GI Oncology
News
Large study probes colonoscopy surveillance intervals
Low-risk adenomas show same risk of colorectal cancer as no adenomas, so they may need no adjustment to surveillance interval.
News
GALAD score predicts NASH-HCC more than a year in advance
The score, which combines sex, age, alpha-fetoprotein-L3, alpha-fetoprotein, and des-gamma-carboxyprothrombin is blood based and can replace...
From the Journals
Colorectal cancer cases spike after start of routine screening
The rise of colorectal cancer between 49 and 50 years of age suggests a preclinical burden of undetected cases.
Conference Coverage
Dual immunotherapy goes the distance in MSI-H colorectal cancer
SAN FRANCISCO – At a median follow-up of almost 20 months, combination nivolumab and ipilimumab remained highly active as first-line therapy for...
Conference Coverage
Blood test may advance diagnosis of GI cancers
The Circulating Cell-free Genome Atlas (CCGA) study finds that a multicancer assay using targeted methylation sequencing of plasma cell-free DNA...
Conference Coverage
Three or more nonadvanced adenomas no longer spell increased CRC risk
SAN ANTONIO – High-definition colonoscopy changes risk equation for metachronous advanced neoplasia.
Opinion
ctDNA and avapritinib in GI cancer management
Dr. Alan P. Lyss breaks down how circulating tumor DNA monitoring and the approval of a new targeted agent are both set to change management of...
From the Journals
Eradicating H. pylori may cut risk of gastric cancer
Treatment without eradication was associated with an increase in risk.
News
FDA approves avapritinib for adults with GIST with PDGFRA mutation
Approval was based on an overall response rate of 84% among 43 adults with unresectable or metastatic gastrointestinal stromal tumors and PDGFRA...
From the Journals
Unique T cell populations pinpointed in hepatocellular carcinoma tissue
Cells identified in tumors could represent target of immunotherapy and serve as “prognostic indicator of therapy responsiveness,” according to...
From the Journals
ctDNA outmatches CEA for detection of colorectal cancer recurrence
The sensitivity of circulating tumor DNA for recurrence was 66.0%, compared with 31.9% for carcinoembryonic antigen, in an observational study...